1. Home
  2. SNGX vs STRR Comparison

SNGX vs STRR Comparison

Compare SNGX & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • STRR
  • Stock Information
  • Founded
  • SNGX 1987
  • STRR 1985
  • Country
  • SNGX United States
  • STRR United States
  • Employees
  • SNGX N/A
  • STRR N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • SNGX Health Care
  • STRR Health Care
  • Exchange
  • SNGX Nasdaq
  • STRR Nasdaq
  • Market Cap
  • SNGX 7.4M
  • STRR 7.0M
  • IPO Year
  • SNGX 1987
  • STRR N/A
  • Fundamental
  • Price
  • SNGX $2.35
  • STRR $2.29
  • Analyst Decision
  • SNGX
  • STRR
  • Analyst Count
  • SNGX 0
  • STRR 0
  • Target Price
  • SNGX N/A
  • STRR N/A
  • AVG Volume (30 Days)
  • SNGX 619.7K
  • STRR 25.4K
  • Earning Date
  • SNGX 03-14-2025
  • STRR 11-19-2024
  • Dividend Yield
  • SNGX N/A
  • STRR N/A
  • EPS Growth
  • SNGX N/A
  • STRR N/A
  • EPS
  • SNGX N/A
  • STRR N/A
  • Revenue
  • SNGX $364,183.00
  • STRR $50,375,000.00
  • Revenue This Year
  • SNGX N/A
  • STRR $15.58
  • Revenue Next Year
  • SNGX $76.64
  • STRR $36.27
  • P/E Ratio
  • SNGX N/A
  • STRR N/A
  • Revenue Growth
  • SNGX N/A
  • STRR 2.22
  • 52 Week Low
  • SNGX $1.83
  • STRR $2.06
  • 52 Week High
  • SNGX $14.88
  • STRR $5.35
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 34.04
  • STRR 45.36
  • Support Level
  • SNGX $2.03
  • STRR $2.10
  • Resistance Level
  • SNGX $3.44
  • STRR $2.39
  • Average True Range (ATR)
  • SNGX 0.33
  • STRR 0.12
  • MACD
  • SNGX -0.08
  • STRR 0.04
  • Stochastic Oscillator
  • SNGX 19.39
  • STRR 66.67

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About STRR Star Equity Holdings Inc.

Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.

Share on Social Networks: